Paradigm Biopharmaceuticals Ltd (ASX:PAR) chairman Graeme Kaufman has tendered his resignation as a director for personal and health reasons.
Kaufman joined the Paradigm board prior to its IPO and ASX listing and has contributed strongly to Paradigm's development and success, reflected in the company this month moving into the ASX 300.
Thanked for contribution
Chief executive officer Paul Rennie said: “Graeme has overseen the development of PAR since the IPO and I would like to personally thank Graeme for his contribution to Paradigm.”
The Paradigm board has appointed CEO Paul Rennie as its interim chairman.
Clinical and commercial expertise
On June 3, the company added to the clinical and commercial development expertise of its management team through the appointments of Jeannie Joughlin and Michael Imperiale.
The appointments add considerable experience and strengthen the team as the company prepares phase-3 trials in osteoarthritis and mucopolysaccharidosis.
Rennie said at the time: “It is a very exciting time for Paradigm and to add two highly experienced staff members whose diverse skills will complement the current Paradigm team is very pleasing.”
